Literature DB >> 3208208

Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis.

D W Paty1.   

Abstract

Magnetic resonance imaging (MRI) has been shown to be a good method of visualizing the lesions in MS. We have studied several applications of MRI to the evaluation of patients and experimental models. In diagnosis, MRI is the most sensitive test for the demonstration of dissemination of lesions in space. Pathological correlation studies show that MRI reliably measures the extent of chronic demyelination. Experimental studies show that MRI detects acute inflammatory lesions and measures their evolution. MRI also is a reliable measure of the extent of the MS process, serial MRI scans detect evidence of disease activity in MS not always disclosed by clinical evaluation. MRI will have an enormous future impact on the evaluation of patients in clinical studies and in understanding the evolution of pathological processes.

Entities:  

Mesh:

Year:  1988        PMID: 3208208     DOI: 10.1017/s0317167100027724

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

1.  Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.

Authors:  Francesco Sardanelli; Andrea Iozzelli; Caterina Losacco; Alessandra Murialdo; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

2.  Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Authors:  Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham
Journal:  Neuroimage       Date:  2017-01-11       Impact factor: 6.556

3.  New perspectives in multiple sclerosis.

Authors:  D W Paty
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

4.  Characteristics of neurological and cognitive status in patients with multiple sclerosis in relation to the location and volumes of demyelination foci and the severity of brain atrophy.

Authors:  K K Mineev; L N Prakhova; A G Il'ves; G V Kataeva; A M Petrov; T N Reznikova; A V Pozdnyakov; I D Stolyarov
Journal:  Neurosci Behav Physiol       Date:  2009-01

5.  An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation Strategies.

Authors:  Lori Saslow; David K B Li; June Halper; Brenda Banwell; Frederik Barkhof; Laura Barlow; Kathleen Costello; Peter Damiri; Jeffrey Dunn; Shivraman Giri; Micki Maes; Sarah A Morrow; Scott D Newsome; Jiwon Oh; Friedemann Paul; Patrick Quarterman; Daniel S Reich; Jason R Shewchuk; Russell Takeshi Shinohara; Wim Van Hecke; Kim van de Ven; Mitchell T Wallin; Jerry S Wolinsky; Anthony Traboulsee
Journal:  Int J MS Care       Date:  2020-10-27

Review 6.  MRI: role in optimising treatment.

Authors:  Anthony Traboulsee
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

7.  Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis.

Authors:  Francesco Manfredonia; Livia Pasquali; Angela Dardano; Alfonso Iudice; Luigi Murri; Fabio Monzani
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

Review 8.  Clinical trials in multiple sclerosis: milestones.

Authors:  Yinan Zhang; Amber Salter; Gary Cutter; Olaf Stuve
Journal:  Ther Adv Neurol Disord       Date:  2018-07-09       Impact factor: 6.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.